您要查找的是不是：
- Aleukemic myelogenous leukemia 非白血性骨髓性白血病
- This is less common with acute myelogenous leukemia. 而这种情况在急粒患者中发生的比例更小。
- Such massive splenomegaly is usually indicative of some myeloproliferative disease such as chronic myelogenous leukemia or myelofibrosis. 这样的脾肿大通常预示有骨髓增生型疾病，例如慢性髓性白血病或骨髓纤维化。
- Effects of Camptothecin, Amsacrine and Vinblastine on the cell cycle of lymphocytic or myelogenous leukemia cells. 喜树碱、胺苯吖啶、长春花碱对淋巴细胞性和髓样白血病细胞周期的影响。
- CNL was a rare clinicopathologic entity that could distinguished from chronic myelogenous leukemia. CNL是一种少见类型的慢性白血病 ,其特点与慢性髓细胞白血病不同 ;
- The BCR/ABL fusion gene plays an important role in the malignant transformation of chronic myelogenous leukemia (CML). 融合基因 BCR/ABL在慢性粒细胞白血病的恶性转化过程中起着主导作用 .
- It is approved for the treatment of chronic myelogenous leukemia (CML) and hairy cell leukemia. 它被批准用于慢性髓细胞白血病和毛细胞白血病的治疗。
- Objective To explore the expression and significance of WT1 gene in patients with acute myelogenous leukemia(AML). 目的探讨WT1基因在急性髓细胞白血病(AML)患者中的表达及其与临床治疗和预后的关系。
- The first is the blood cell-forming organ.This is the site where myelogenous leukemia begins. 首先是血细胞生成器官，是髓细胞性白血病的发生部位。
- Leukemia is a type of cancer.There are 4 main types of leukemia.Acute myelogenous leukemia (AML) is 1 of the 4 types. 白血病是一种恶性肿瘤，可分为4个主要类型，其中之一即为急性髓细胞白血病。
- At high power, the bone marrow of a patient with acute myelogenous leukemia is seen here. 在高倍镜下，见到的是急性髓母细胞白血病骨髓。
- No bcr/abl gene was revealed in the controls, while in the chronic myelogenous leukemia(CML) group the positive rate was 89.5%(17/19). 对照组bcr/abl基因表达均为阴性。 慢性粒细胞白血病 (CML)病人bcr/abl基因表达阳性率为 89.;5%25 (1 7/ 1 9);经治疗达临床缓解者 8例;bcr/abl基因表达均值为 (2
- The bcr/abl gene has been documented as having a significant role to play in the pathogenesis of Ph+ chronic myelogenous leukemia (CML). Ph~+慢性粒细胞白血病(CML)的bcr/abl融合基因在其发病机制中具有重要作用。
- Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia. 目的探讨急性髓性白血病在经过混合造血干细胞移植(mixed-HSCT)后,应用供体淋巴细胞输注(DLI)+白介素-2(IL-2)作为后续免疫生物治疗措施的意义。
- Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease of transformed hematopoietic progenitor cells. 慢性粒细胞白血病(chronic myelogcnous leukemia,CML)是一种以髓系细胞受累为主的多能造血干细胞的克隆性疾病。
- Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder due to an acquired abnormality in a pluripotential hematopoietic stem cell. 慢性粒细胞白血病(Chronic Myelogenous Leukemia，CML，简称慢粒)是一种起源于多能干细胞异常克隆的恶性增殖性疾病。
- Objective To investigate the relationship between cyclin D2 and P210 BCR/ABL tyrosine kinase in chronic myelogenous leukemia(CML). 目的 研究cyclinD2基因表达与慢性粒细胞白血病 (CML)特征性的P2 10 BCR ABL蛋白酪氨酸激酶活性之间的相关性。
- Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently. Mixed-HSCT后应用DLI+IL-2,可能是有效提高长期生存率的免疫生物治疗措施之一。
- The combination regimen of HHT and Ara c is effective and economical in patient with late chronic-phase chronic myelogenous leukemia(CML). 高三尖杉酯碱联合低剂量阿糖胞苷治疗慢粒白血病急变简便 ,经济 ,有效
- Title： Proliferation of reticulin fibre and megakaryocyte in bone marr ow of Guangix,patients with chronic myelogenous leukemia. 关键词：慢性白血病；骨髓纤维化；网硬蛋白纤维；巨核细胞；骨髓活组织检查
